Maxwell Biosciences, Makers of CLAROMER, Hire John Lord, Ph.D., as VP of Research and Development
Austin, Texas based biotechnology company Maxwell Biosciences have announced the hiring of Dr. John Lord as Vice President…
Browsing Tag
Maxwell Biosciences, founded in 2016, is a preclinical-stage drug platform firm that is actively developing an all-new CLAROMER™ biotechnology platform that creates proprietary, virucidal, smaller molecule, non-peptide chemicals known as peptoids.
This novel biotechnology emulates the power and flexibility of natural antimicrobial peptides while delivering pharmacological benefits of a small molecule. The organization is led by a group of distinguished scientists and executives.
U.S. government-funded labs recently confirmed that a study evaluating the virucidal activity of Maxwell’s lead drug candidate has shown direct virucidal efficacy against SARS-CoV-2.
Maxwell’s drugs appear to have a wide therapeutic window in humans, according to recent live mouse safety data from Texas A&M.
Before this, Maxwell’s drugs have been found to show direct activity against the structure of the Herpes Simplex Virus (HSV-1).
Maxwell Pharmaceuticals, Inc.’s drug platform is bolstered by a granted patent portfolio that gives it a significant advantage in the fight against emerging viral pandemics.